Insights

Gathering insights about Abpro…

Similar companies to Abpro

Abpro Tech Stack

Abpro uses 8 technology products and services including Open Graph, MySQL, oEmbed, and more. Explore Abpro's tech stack below.

Open Graph
Content Management System
MySQL
Database
oEmbed
Dev Tools
Skrollr
Javascript Libraries
jQuery
Javascript Libraries
HTTP/3
Web & Portal Technology
GoDaddy
Web Hosting
TablePress
Web Platform Extensions

Media & News

Abpro (NASDAQ:ABP) Stock Price Up 0.2% – Still a Buy?
Shares of Abpro Holdings Inc. (NASDAQ: ABP - Get Free Report) were up 0.2% during trading on Thursday. The stock traded as high as $4.80 and last traded at $4.79. Approximately 12,770 shares changed hands during trading, a decline of 47% from the average daily volume of 24,173 shares. The stock had previously closed at
Dec 19, 2025 | www.defenseworld.net
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents Abpro's first IND submission for a phase 1 trial in a solid tumor indication, and is being co-developed by Abpro and Celltrion, Inc. BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP, “Abpro”), a biotechnology company developing novel breakthrough therapeutics for solid tumors, together with its co-development partner Celltrion, Inc., today announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for ABP-102/CT-P72, a HER2 × CD3 T cell engager engineered with optimized CD3 and HER2 binding to improve tumor selectivity.
Dec 15, 2025 | www.globenewswire.com
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
BURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology company advancing next-generation antibody therapies, today announced that it has received formal notification from the Nasdaq Hearings Panel granting the Company an extension to allow additional time to regain full compliance with Nasdaq listing requirements.
Dec 09, 2025 | www.globenewswire.com
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
BURLINGTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Abpro Corporation (Nasdaq: ABP) (“Abpro”) and Celltrion, Inc. (“Celltrion”) today announced that they will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, being held November 6–10, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland.
Nov 04, 2025 | www.globenewswire.com
Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025
Achieved ~60% reduction in operating costs through a focused cost optimization plan DiversImmune® platform positioned to unlock additional pipeline value Reverse stock split supports Nasdaq compliance and positions company for next phase of growth BURLINGTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology company advancing next-generation antibody therapies, today announced that its previously approved 1-for-30 reverse stock split (the “Reverse Stock Split”) of its common stock became effective at 5:01 p.m.
Nov 03, 2025 | www.globenewswire.com
Abpro Holdings Inc. (NASDAQ:ABP) Sees Large Decrease in Short Interest
Abpro Holdings Inc. (NASDAQ: ABP - Get Free Report) was the recipient of a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 1,690,000 shares, a decline of 47.0% from the September 30th total of 3,190,000 shares. Based on an average daily trading volume, of 7,510,000
Oct 31, 2025 | www.defenseworld.net
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ABP-102/CT-P72 HER2-positive cancers represent up to 30 percent of all cases of breast, gastric, pancreatic, colorectal and other forms of cancer WOBURN, Mass., April 27, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, and Celltrion, a leading biopharmaceutical company, today unveiled preclinical data for ABP-102/CT-P72 in an oral presentation at the American Association for Cancer Research® (AACR) Annual Meeting 2025, in the New Drugs on the Horizon session.
Apr 27, 2025 | www.globenewswire.com

Abpro's Email Address Formats

Abpro uses at least 2 format(s):

Abpro Email Formats	Example	Percentage
FLast@abpro.com	JDoe@abpro.com	98%
First@abpro.com	John@abpro.com	2%
FLast@abpro.co	JDoe@abpro.co	100%

Frequently Asked Questions

What is Abpro's phone number?

You can contact Abpro's main corporate office by phone at

+1-800-396-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Abpro's stock symbol?

Abpro is a publicly traded company; the company's stock symbol is ABP.

What is Abpro's official website and social media links?

Abpro's official website is abpro.co and has social profiles on LinkedIn Crunchbase.

What is Abpro's SIC code NAICS code?

Abpro's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Abpro have currently?

As of December 2025, Abpro has approximately 38 employees across 5 continents, including North AmericaAsiaAfrica. Key team members include Chief Executive Officer And Vice President At Abpro Biotech And Biopharma: J. Y.Ceo: C. M.Chief Medical Officer: R. M.. Explore Abpro's employee directory with LeadIQ.

What industry does Abpro belong to?

Abpro operates in the Biotechnology Research industry.

What technology does Abpro use?

Abpro's tech stack includes Open GraphMySQLoEmbedSkrollrjQueryHTTP/3GoDaddyTablePress.

What is Abpro's email format?

Abpro's email format typically follows the pattern of FLast@abpro.com. Find more Abpro email formats with LeadIQ.

When was Abpro founded?

Abpro was founded in 2007.

Abpro

Q: What is Abpro's official website and social media links?

Abpro's official website is abpro.co. Abpro has social profiles on LinkedIn.

Q: How many employees does Abpro have currently?

Abpro has approximately 38 employees.

Q: What technology does Abpro use?

Abpro's tech stack includes MySQL, Yoast SEO, Open Graph, LiteSpeed Cache, GoDaddy.

Biotechnology ResearchMassachusetts, United States11-50 Employees

We're a public biotech company (Nasdaq: ABP) leveraging our proprietary DiversImmune® and MultiMab platforms to advance next-generation antibody therapeutics for immuno-oncology and ophthalmology. Collaborating with global pharmaceutical and research partners, we're advancing a robust pipeline of innovative treatments. For more information, please visit https://abpro.co/

Company Overview

Phone number: +1-800-396-****
Website: abpro.co
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: ABP
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2007
Employees: 11-50

Media & News

Funding & Financials

$10M$25M
Abpro's revenue is estimated to be in the range of $10M$25M

Funding & Financials

$10M$25M
Abpro's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Abpro

Genmab

Incyte

AstraZeneca

Pandion Therapeutics

Innovent Biologics

Immatics

Atara Biotherapeutics

MorphoSys

Immunomedics

Abpro Tech Stack

Media & News

Abpro (NASDAQ:ABP) Stock Price Up 0.2% – Still a Buy?

Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers

Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives

Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager

Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025

Abpro Holdings Inc. (NASDAQ:ABP) Sees Large Decrease in Short Interest

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

Abpro's Email Address Formats

Frequently Asked Questions

What is Abpro's phone number?

What is Abpro's stock symbol?

What is Abpro's official website and social media links?

What is Abpro's SIC code NAICS code?

How many employees does Abpro have currently?

What industry does Abpro belong to?

What technology does Abpro use?

What is Abpro's email format?

When was Abpro founded?

Abpro

Company Overview

Media & News

Abpro (NASDAQ:ABP) Stock Price Up 0.2% – Still a Buy?

Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers

Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?